Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 3-((6-deoxymannopyranosyl)oxy)-7-(glucopyranosyloxy)-5-hydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-butenyl)-4h-1-benzopyran-4-one
1. 489-32-7
2. Ieariline
3. 5-hydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-en-1-yl)-7-(((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)oxy)-3-(((2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyltetrahydro-2h-pyran-2-yl)oxy)-4h-chromen-4-one
4. Chebi:78420
5. Mfcd00210516
6. Vnm47r2qsq
7. Icariine
8. 3-[(6-deoxy-alpha-l-mannopyranosyl)oxy]-5-hydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-en-1-yl)-4-oxo-4h-chromen-7-yl Beta-d-glucopyranoside
9. 5-hydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)-7-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxychromen-4-one
10. Smr000466309
11. Unii-vnm47r2qsq
12. Horny Goat Weed
13. Epimedium Extract
14. 3-((6-deoxymannopyranosyl)oxy)-7-(glucopyranosyloxy)-5-hydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-butenyl)-4h-1-benzopyran-4-one
15. Epimedii Herba Icariin
16. Spectrum2_001695
17. Spectrum3_001130
18. Spectrum4_001975
19. Spectrum5_000933
20. Icariin, Analytical Standard
21. Bspbio_002599
22. Kbiogr_002475
23. Mls000759413
24. Mls001424083
25. Mls006011789
26. Schembl312615
27. Spectrum1505257
28. Spbio_001650
29. Ambz0238
30. Chembl553204
31. Icariin, >=94% (hplc)
32. Kbio3_002099
33. Dtxsid00964133
34. Hms2051j13
35. Hms2235i20
36. Bcp18807
37. Epimedii Herba Icariin [mi]
38. Ex-a6783
39. Hy-n0014
40. Zinc3960893
41. Bbl010487
42. Bdbm50027363
43. Ccg-38780
44. Stk801622
45. Akos005614005
46. Am85785
47. Ccg-100955
48. Cs-3675
49. Db12052
50. Nc00205
51. Sdccgmls-0066754.p001
52. Ncgc00178583-01
53. 4h-1-benzopyran-4-one, 3-((6-deoxy-alpha-l-mannopyranosyl)oxy)-7-(beta-d-glucopyranosyloxy)-5-hydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-butenyl)-
54. Vs-02526
55. N1705
56. C17555
57. Ab00639912-06
58. 489i327
59. A827628
60. Sr-01000759346
61. Q-100549
62. Q5985057
63. Sr-01000759346-4
64. Brd-k65639003-001-02-5
65. Brd-k65639003-001-05-8
66. Brd-k65639003-001-09-0
67. 3,5-dihydroxy-4\'-methoxy-6\'\',6\'\'-dimethyl-4\'\',5\'\'-dihydropyrano[2\'\',3\'\':7,8]-flavone
68. 3-[(6-deoxy-alpha-l-mannopyranosyl)oxy]-7-(beta-d-glucopyranosyloxy)-5-hydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-buten-1-yl)-4h-1-benzopyran-4-one
69. 4h-1-benzopyran-4-one, 3-((6-deoxy-.alpha.-l-mannopyranosyl)oxy)-7-(.beta.-d-glucopyranosyloxy)-5-hydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-buten-1-yl)-
70. 5-hydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-en-1-yl)-7-(((2s,4s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)oxy)-3-(((3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyltetrahydro-2h-pyran-2-yl)oxy)-4h-chromen-4-one
71. 5-hydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-en-1-yl)-7-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-3-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}-4h-chromen-4-one
72. 5-hydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)-7-((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yloxy)-3-((2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyltetrahydro-2h-pyran-2-yloxy)-4h-chromen-4-one
| Molecular Weight | 676.7 g/mol |
|---|---|
| Molecular Formula | C33H40O15 |
| XLogP3 | 1.7 |
| Hydrogen Bond Donor Count | 8 |
| Hydrogen Bond Acceptor Count | 15 |
| Rotatable Bond Count | 9 |
| Exact Mass | 676.23672056 g/mol |
| Monoisotopic Mass | 676.23672056 g/mol |
| Topological Polar Surface Area | 234 Ų |
| Heavy Atom Count | 48 |
| Formal Charge | 0 |
| Complexity | 1170 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 10 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Icariin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Icariin, including repackagers and relabelers. The FDA regulates Icariin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Icariin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Icariin supplier is an individual or a company that provides Icariin active pharmaceutical ingredient (API) or Icariin finished formulations upon request. The Icariin suppliers may include Icariin API manufacturers, exporters, distributors and traders.
Icariin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Icariin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Icariin GMP manufacturer or Icariin GMP API supplier for your needs.
A Icariin CoA (Certificate of Analysis) is a formal document that attests to Icariin's compliance with Icariin specifications and serves as a tool for batch-level quality control.
Icariin CoA mostly includes findings from lab analyses of a specific batch. For each Icariin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Icariin may be tested according to a variety of international standards, such as European Pharmacopoeia (Icariin EP), Icariin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Icariin USP).
LOOKING FOR A SUPPLIER?
